Insider buying last 90 days
No open-market insider purchases were filed for BCPC in the last 90 days.
From Form 4 filings, dated to when each was filed.
Nov 13 close
Balchem's week was shaped by a strong third-quarter report, with record net income of $46.7 million and revenue growth of 8.6%, alongside adjusted EBITDA up 12.5% to $80.3 million at a record 27.6% margin. The Human Nutrition & Health segment led results, posting 8% revenue growth and 11% higher operating income. The stock also touched a new 52-week high of $183.9, reflecting roughly 19.94% appreciation over the past year, and commentary noted a significant share repurchase alongside the quarterly results, with some views describing the stock as near fair value following its run and others flagging capacity utilization and market risks.
BCPC closed at $175.99, up 0.9%, sitting above both its 50-day average of $169.94 and 200-day average of $169.56, with the 50-day above the 200-day. The GekkoIndex reads 53.4, placing it in the Neutral zone. Shares trade 2.4% below Gekko Fair Value of $180.23, within the 52-week range of $152.42 to $186.15.
The next earnings date falls on 19 February 2027, 101 days out, placing it outside a typical 20-trading-day holding window. Over the last 90 days, Congressional activity shows 1 buy and 0 sells. Seasonality from this point in the calendar has averaged a 0.9% gain over the next 20 trading days across 4 years, rising in 2 of them. A single analyst carries a buy rating with a consensus target of $213.5, implying 21.3% upside from current levels.
Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.
Balchem scores 3 supportive, 3 mixed and 0 headwinds across the 6 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
3 supportive3 mixed0 headwinds
Above 50 and 200-day
Close $173.14 is above the 50-day ($169.86) and 200-day ($169.67) averages, and the 50-day is above the 200-day.
See the chart58.3, Neutral
Reading 58.3 is in the Neutral zone.
See the GekkoIndex1.4% below
Price is within 5% of Gekko Fair Value (1.4% below).
See fair valueLeans bullish
Last 90 days: Congress 1 buy / 0 sales.
See smart moneyReports in 96 days
Next report Feb 19, 2027, 96 days away — outside a typical 20-trading-day hold.
See earnings+1.2% on average
From this point in the calendar, the next 20 trading days averaged +1.2% over 4 years, rising in 2 of them.
See seasonalityA description of current data, not a recommendation. How this page works
Balchem closed at $173.14 on Nov 13, 2026, +5.0% over the past year, inside a 52-week range of $152.42 to $186.15.
Use the left and right arrow keys to read daily values.
Put BCPC on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Balchem produces specialty ingredients that reach into food, pharmaceutical, animal care, medical sterilization, plant nutrition, and industrial uses around the world. Among its offerings are encapsulated nutrients, vitamin K2, choline-derived compounds, mineral chelates, and gases applied in sterilizing medical equipment, which together give the company recognition across several markets.
Its operations fall into three areas. One focuses on ingredients for food and drink makers, supplying items such as dried powders, lipid blends, flavor systems, and bases used in dairy, juice, chocolate, cereal, and ice cream production. Another serves animal health, offering nutrient delivery methods and absorption-enhancing chelation technology for livestock and pets alike. A third handles specialty distribution, moving ethylene oxide and ammonia for hospital sterilization work, fumigants that guard nuts, spices, cacao, and dried fruit from pests and spoilage, and mineral chelates for agricultural crops. Balchem reaches its customers directly and also relies on outside distributors and agents to move its goods to market.
Founded in 1967, the company keeps its headquarters in Montvale, New Jersey, and its stock is listed on the NASDAQ under the ticker BCPC.
Balchem’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 58.3, in the Neutral zone, up 5.9 points over five sessions.
Up 5.9 points over five sessions.
Reading for Nov 13, 2026
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 29 | +1.0% | +3.8% | ||
| Accumulation | 157 | +0.7% | +3.8% | ||
| Neutral (current zone) | 361 | 0.0% | −0.6% | ||
| Distribution | 24 | +0.9% | −0.6% | ||
| Selling | 4 | Too few readings yet | |||
Average BCPC share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
Balchem trades 1.4% below Gekko Fair Value of $175.56, so the shares are about fair value on Gekko’s estimate.
Gekko’s own estimate of what Balchem shares are worth, recalculated every trading day.
$175.56
Gekko Fair Value, Nov 14, 2026
1.4% below fair value · About fair value
At the end of Aug 2026 the price was 4.1% below the estimate.
No open-market insider purchases were filed for Balchem, and members of Congress disclosed 1 purchase and 0 sales, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
No open-market insider purchases were filed for BCPC in the last 90 days.
From Form 4 filings, dated to when each was filed.
1trade disclosed: 1 purchase and 0 sales.
| Member | Amount | Disclosed |
|---|---|---|
| Gilbert Cisneros House, CA, purchase | $1,001 - $15,000 | Oct 12 traded Sep 17 |
From congressional disclosures, which report amounts as ranges.
Balchem has been buying back its own shares.
From company filings.
Balchem reports on Feb 19, 2027 (96 days away), and beat the EPS estimate in 7 of its last 8 reports.
Feb 19, 2027
96 days away
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Apr 24, 2026 | $1.33 est $1.24 | — | −0.8% |
| Feb 13, 2026 | $1.31 est $1.18 | $263.6M est $259.6M | +1.1% |
| Oct 21, 2025 | $1.35 est $1.36 | $267.6M est $259.6M | +0.4% |
| Jul 24, 2025 | $1.27 est $1.11 | $255.5M est $257.6M | +0.4% |
| May 1, 2025 | $1.22 est $1.22 | $250.5M est $245.7M | +3.4% |
| Feb 14, 2025 | $1.13 est $1.11 | — | +1.8% |
| Oct 25, 2024 | $1.13 est $1.11 | $239.9M est $235.1M | +2.8% |
| Jul 26, 2024 | $1.09 est $1.03 | $234.1M est $239.7M | +3.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Analysts’ average 12-month price target for Balchem is $213.50, +23.3% from the last close, from 1 firm rating the stock in the last 90 days.
Each firm’s latest rating in the last 90 days: 1 firm.
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 26 | H.C. Wainwright | $210 | +21.3% |
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Over the next 20 trading days from Nov 14, Balchem averaged +1.2% across the last 4 years, rising in 2 of them.
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +0.6% | 3 of 4 |
| Next 10 trading days | −1.6% | 1 of 4 |
| Next 15 trading days | −1.3% | 2 of 4 |
| Next 20 trading days | +1.2% | 2 of 4 |
| Next 30 trading days | +0.1% | 2 of 4 |
For scale, BCPC’s typical 20-trading-day move in either direction is about 4.7%.
Balchem’s market cap is $5.52B, with a P/E ratio of 32.5 and revenue of $1.11B over the last twelve months.
1 headline about Balchem from the past week, newest first, each linking to the publisher.
Balchem’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| PEPPepsiCo | Neutral | 3.2% below |
| MDLZMondelez International | Neutral | 17.4% below |
| HSYHershey | Neutral | 22.9% below |
| IFFInternational Flavors & Fragrances | Accumulation | 2.7% below |
| SJMJ.M. Smucker | Neutral | 16.6% above |
| MKCMcCormick | Accumulation | 15.7% below |
A peer links to its own page where one exists.
Balchem’s market cap is $5.52B at the Nov 13, 2026 close of $173.14, with 31.88M shares outstanding. The shares trade on a P/E ratio of 32.5.
The consensus analyst 12-month price target for Balchem is $213.50, +23.3% from the last close. Of the 1 firm that rated the stock in the last 90 days, 1 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
On Gekko’s estimate Balchem is about fair value: the Nov 13, 2026 close of $173.14 is 1.4% below Gekko Fair Value of $175.56. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
Balchem is expected to report on Feb 19, 2027 (96 days away). Analysts expect earnings of $1.41 per share on revenue of $286.9M. Balchem beat the earnings estimate in 7 of its last 8 reports, moving 1.8% on average across the report.
Balchem’s 52-week high is $186.15 and its 52-week low is $152.42; it closed at $173.14 on Nov 13, 2026, +5.0% over the past year.
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (trend, smart money and earnings risk), 3 as mixed (gekkoindex, fair value and seasonality). The checklist is a description of current data, not a recommendation.
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,475 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.Type a ticker or company name. Press Esc to close.